Cabaletta Bio to Join Jefferies Global Healthcare Conference

Philadelphia, May 29, 2024— Cabaletta Bio, Inc. (Nasdaq: CABA), a biotechnology company at the clinical stage, is pioneering the development of targeted cell therapies aimed at curing autoimmune diseases. The company announced that its Chief Executive Officer, Steven Nichtberger, M.D., will be engaged in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for Wednesday, June 5, 2024, at 11:00 a.m. ET in New York, NY. Attendees can access a live webcast of the presentation on the company’s website under the News and Events section, with replays available for a period of 30 days.

Cabaletta Bio specializes in the innovation of engineered T cell therapies which may offer profound and lasting treatments, potentially even cures, for individuals suffering from autoimmune diseases. Their CABA™ platform is comprised of two main strategies. The first, CARTA (chimeric antigen receptor T cells for autoimmunity), is spearheaded by CABA-201. This product candidate, a 4-1BB-containing fully human CD19-CAR T, is currently under evaluation in the RESET™ clinical trials. These trials target a range of autoimmune conditions including systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis. Additionally, the RESET-PV™ sub-study within the DesCAARTes™ trial is investigating this candidate for the treatment of pemphigus vulgaris.

The second strategy is CAART (chimeric autoantibody receptor T cells), which includes several candidates that are already in clinical stages. Among these are DSG3-CAART, designed for mucosal pemphigus vulgaris, and MuSK-CAART, targeting MuSK-associated myasthenia gravis. The overarching goal of the CABA™ platform is to create therapies that not only provide deep and durable responses but also offer potentially curative solutions for a wide array of autoimmune diseases.

Cabaletta Bio’s operational base, including its headquarters and laboratories, is situated in Philadelphia, PA. The company continues to advance its groundbreaking research and development efforts, striving to transform the therapeutic landscape for autoimmune disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!